Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections

Authors Mary L Townsend, Melanie W Pound, Richard H Drew

Published 15 January 2008 Volume 2007:3(6) Pages 1059—1070

Mary L Townsend1, Melanie W Pound1, Richard H Drew1,2,3
1Campbell University School of Pharmacy, Buies Creek, NC, USA; 2Duke University Medical Center, Durham, NC, USA; 3Duke University School of Medicine, Durham, NC, USA
Abstract: Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents a new option for the treatment of complicated intra-abdominal and complicated skin and skin structure infections. It displays favorable activity in vitro against the most common causative Gram-positive, Gram-negative and anaerobic pathogens. In addition, tigecycline demonstrates activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and organisms (such as Escherichia coli and Klebsiella pneumoniae) producing extended-spectrum beta-lactamases. Tigecycline lacks activity in vitro against Pseudomonas and Proteus spp. In randomized clinical trials, tigecycline administered intravenously twice daily has demonstrated efficacy similar to comparators for a variety of complicated skin and skin structure and complicated intra-abdominal infections. The potential for significant drug interactions with tigecycline appears to be minimal. Dosing adjustment is needed for patients with severe hepatic impairment. The predominant side effect associated with its use to date has been gastrointestinal intolerance (nausea and vomiting).
Keywords: tigecycline, intra-abdominal infections, complicated skin and skin structure infections

Download Article [PDF] 

Readers of this article also read:

Comparison of different intraocular pressure measurement techniques in normal eyes, post surface and post lamellar refractive surgery

Shousha SM, Abo Steit MA, Hosny MH, Ewais WA, Shalaby AM

Clinical Ophthalmology 2013, 7:71-79

Published Date: 8 January 2013

Optimizing pain control through the use of implantable pumps

Wilfried Ilias, Boris Todoroff

Medical Devices: Evidence and Research 2008, 1:41-47

Published Date: 21 October 2008

Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication?

Tarsila CR Ribeiro, Julio MF Chebli, Mario Kondo, Pedro Duarte Gaburri, Liliana Andrade Chebli, Ana Cristina Amaral Feldner

Therapeutics and Clinical Risk Management 2008, 4:919-925

Published Date: 10 October 2008

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate

Ismail A Mohammed, Alastair J Hutchison

Therapeutics and Clinical Risk Management 2008, 4:887-893

Published Date: 10 October 2008

Editorial Foreword || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:705-706

Published Date: 15 November 2007

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Shimon Lecht, Simon Haroutiunian, Amnon Hoffman, Philip Lazarovici

Therapeutics and Clinical Risk Management 2007, 3:467-474

Published Date: 15 July 2007